ZZPZH(SH:600436) Zhong Zheng Wang·2026-02-10 11:53Core Viewpoint - The collaboration between Pianzaihuang and Shanghai Lidao Pharmaceutical Technology Co., Ltd. focuses on the development of the innovative drug PZH2107 for the treatment of fibromyalgia, which has entered the Phase II clinical trial stage [1][2]. Group 1: Company Developments - Pianzaihuang announced the completion of the first subject enrollment for the Phase II clinical trial of PZH2107, which is designed as a randomized, double-blind, placebo-controlled, multi-center study [1]. - The drug PZH2107 is available in two dosages: 5mg and 20mg, specifically targeting fibromyalgia treatment [1]. - The clinical trial protocol has received approval from the ethics committee of the Beijing Union Medical College Hospital, with the first subject enrolled on February 8, 2026 [1]. Group 2: Industry Insights - Fibromyalgia is a common chronic pain syndrome with a prevalence rate of 2%-4% in the general population, often accompanied by fatigue, sleep, and emotional disorders [2]. - The fibromyalgia treatment market is projected to reach $4.69 billion by 2035, according to ResearchNester [2]. - Current first-line treatments, such as pregabalin, duloxetine, and milnacipran, only partially alleviate symptoms and are associated with significant side effects, indicating an unmet clinical need for more effective treatment options [2].